The two companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis
Called ORAiCLE, it can assess the cardiovascular risk of an individual through a retinal scan, more accurately than the current gold standard.
FDA-cleared AI algorithms that detect leading indicators of heart disease are now available to healthcare professionals in the all-new Eko app.
Data published in PLOS One shows continuous monitoring leads to earlier diagnosis and prevents adverse cardiac events, furthering the case for cardiac screening.
The company's device now detects six times as many cardiac conditions as any other personal ECG...
The team will use AI analysis of ultrasound heart scans to identify the markers of heart failure and develop an image analysis risk prediction model.
Sidekick develops gamified digital therapeutic solutions and programs, designed to transform chronic disease management across multiple therapeutic areas.
The redesigned Eko CORE boasts active noise cancellation, sleeker design, and powerful software to allow for more effective screening for heart disease.
The two companies aim to collaborate on solutions providing early warnings, enabling the identification of patients that could otherwise go undiagnosed.
The company has also unveiled the Omron Blood Pressure Monitor + EKG, the first single at-home device in the U.S. that measures blood pressure and EKG.